Carvedilol preserved peak systolic strain compared to the control group, indicating a protective effect against anthracycline-induced cardiotoxicity in breast cancer patients during 6 months of therapy.
RCT (n=80)
null
Computer-generated sequence
No
Does carvedilol prevent anthracycline-induced cardiotoxicity assessed by strain imaging in female patients with breast cancer?
Carvedilol administration during anthracycline therapy preserves longitudinal left ventricular systolic function as detected by strain imaging, suggesting a protective effect against early subclinical cardiotoxicity.
Effect estimate: null (95% CI null)
p-value: p=<0.005
These results indicate that carvedilol has a protective effect against the cardiotoxicity induced by ANT.
Elitok et al. (Mon,) conducted a rct in Breast cancer (n=80). Carvedilol vs. Placebo was evaluated on Change in peak systolic strain and strain rate (null, 95% CI null, p=<0.005). Carvedilol preserved peak systolic strain compared to the control group, indicating a protective effect against anthracycline-induced cardiotoxicity in breast cancer patients during 6 months of therapy.